NPM1-Mutated Acute Myeloid Leukemia: Recent Developments and Open Questions.

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Somatic mutations in the nucleophosmin (NPM1) gene are prevalent in de novo acute myeloid leukemias (AMLs), particularly those with a normal karyotype.
• NPM1 mutations are now recognized as AML-defining in recent classifications, highlighting their significance.
• NPM1 mutational load is a critical indicator of disease status and is valuable for monitoring minimal/measurable residual disease (MRD).

Purpose of the Study:

• To review recent advancements in NPM1-mutated AML.
• To discuss the biological significance of NPM1 mutations and their role in disease progression and treatment response.
• To identify areas requiring further investigation in NPM1-mutated AML.

Main Methods:

• Review of current literature on NPM1-mutated AML.
• Analysis of classification schema changes (WHO, ICC).
• Discussion of molecular mechanisms, including HOX/MEIS1 overexpression and NPM1 cytoplasmic localization (NPM1c).

Main Results:

• NPM1 mutations are central to AML classification and MRD monitoring.
• High-sensitivity methods are crucial for detecting NPM1 mutant alleles for MRD assessment.
• NPM1-mutated AML cells depend on HOX/MEIS1 overexpression, linked to NPM1c, suggesting therapeutic vulnerabilities.

Conclusions:

• NPM1 mutations are a defining feature of a significant AML subset.
• Understanding the biology of NPM1 mutations, particularly NPM1c and HOX/MEIS1 regulation, is crucial for effective MRD monitoring and treatment.
• Novel therapeutic agents targeting menin and XPO1 show promise for NPM1-mutated AML.